Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
Two cycles of neoadjuvant osimertinib did not meet its primary endpoint of ORR. Neoadjuvant osimertinib is a feasible approach with a manageable safety profile in resectable EGFR-mutant NSCLC.
Authors
- Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
- Hyo Sup Shim (ORCID: https://orcid.org/0000-0002-5718-3624)
- Jii Bum Lee (ORCID: https://orcid.org/0000-0001-5608-3157)
- Sun Min Lim (ORCID: https://orcid.org/0000-0001-7694-1593)
- Sumedha Sudhaman (ORCID: https://orcid.org/0000-0001-9266-7096)
- Byung Jo Park (ORCID: https://orcid.org/0000-0001-5217-4764)
- Sharlene Velichko (ORCID: https://orcid.org/0000-0002-0133-100X)
- Sujin Choi (ORCID: https://orcid.org/0000-0002-7440-6551)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Chang Young Lee (ORCID: https://orcid.org/0000-0002-2404-9357)
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
- Natera (United States) (US)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1016/j.jtho.2024.12.023
- Citations
- 18
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 7.54
Funders
- MedImmune